The Management

Julian Attfield Stravencon imageJulian Attfield Chief Financial Officer, Company Secretary and Director
Julian has 17 years of experience working as a Chief Financial and Chief Executive Officer in the global biopharmaceutical industry, and has particular expertise in working with start-ups and Chinese and Indian companies. 


Julian was CFO and then CEO at GeneMedix plc, (now Reliance GeneMedix plc) , an Indian AIM-listed  (Alternate Investment Market) biopharmaceutical  company, where he developed a range of biosimilar (generic biopharmaceutical) products for registration in the EU, and set up EU approved manufacturing (EU cGMP). GeneMedix floated on the Official List of the London and Singapore Stock Exchanges, acquired and divested a business in China, and set up manufacturing joint ventures in Europe and Asia. Julian led the company into an acquisition by Reliance Life Sciences, part of the large Reliance Industries Group of India, and a move onto the AIM market.


Previously, he was Director of Finance and Administration with Sigma-Genosys Ltd, a manufacturer of biomolecules, taking them from start-up to a trade sale to Sigma Aldrich. He was recently the interim Chief Financial Officer to a portfolio of early stage companies such as Smart Holograms Ltd, a UK developer of sensor holograms for use in healthcare diagnostics. He was UK director for the AIM flotation of BHK Inc, a Korean stem cell company.

Julian has a BA degree in Modern Languages from Exeter University and post graduate studies from Cambridge University, U.K., and qualified as a Chartered Accountant with Arthur Andersen (now part of Deloitte & Touche).


Thank you

Thank you

Copyright © Stravencon Limited 2010-2015. All rights reserved.
Home   |   About Us   |   Products   |   Services   |   Media Centre   |   Contact  |  Privacy  |  Terms 

English   中文      
Please login first
or Register
Please register
or Login
Thank you for registering.
Please check your email address and password again.
This Email address is already logged on our system. Please enter in a new one.